Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Ot-551. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 4/20 | 0.48 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7508350 | 0.98 | GAA (0.46) | GAAHTTL3MBTL1KDM4ETSHR | |
| Ot-551 SCHEMBL3692374 | 0.98 | GAA (0.46) | GAAHTTL3MBTL1KDM4ETSHR | |
| SCHEMBL1535623 | 0.98 | GAA (0.46) | GAAHTTL3MBTL1KDM4ETSHR | |
| SCHEMBL19976794 | 0.92 | HTT (0.42) | GAAHTTL3MBTL1TSHRKMT2A | |
| SCHEMBL19636872 | 0.92 | GAA (0.42) | GAAHTTL3MBTL1TSHRKMT2A | |
| SCHEMBL19884611 | 0.90 | GAA (0.41) | GAAHTTL3MBTL1TSHRKMT2A | |
| SCHEMBL19636873 | 0.90 | GAA (0.43) | GAAHTTL3MBTL1TSHRKMT2A | |
| SCHEMBL13554257 | 0.89 | GAA (0.40) | GAAHTTL3MBTL1TSHRKMT2A | |
| SCHEMBL17931223 | 0.88 | GAA (0.39) | GAAHTTL3MBTL1 | |
| SCHEMBL22241054 | 0.88 | GAA (0.39) | GAAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240050371-A1 | W/O/W MICROEMULSIONS FOR OCULAR ADMINISTRATION | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2024-02-15 | — | — | US | claimed |
| US-20210386722-A1 | Treatment of Covid-19 with Nitroxides | PROCTOR PETER HERBERT (US) | 2021-12-16 | — | — | US | claimed |
| US-20200383915-A1 | W/O/W MICROEMULSIONS FOR OCULAR ADMINISTRATION | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2020-12-10 | — | — | US | claimed |
| US-7589107-B2 | Amelioration of vitrectomy-induced cataracts | OTHERA HOLDING, INC. (US) | 2009-09-15 | — | — | US | claimed |
| US-20080312283-A1 | Use of Hydroxylamine Derivates for Inhibiting Vitrectomy-Induced Cataracts | OTHERA PHARMACEUTICALS, INC. (US) | 2008-12-18 | — | — | US | claimed |
| US-20060292190-A1 | Amelioration of vitrectomy-induced cataracts | OTHERA PHARMACEUTICALS, INC. (US) | 2006-12-28 | — | — | US | claimed |
| WO-2006127592-A2 | USE OF HYDROXYLAMINE DERIVATES FOR INHIBITING VITRECTOMY-INDUCED CATARACTS | OTHERA PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | WO | claimed |
| US-20250041219-A1 | W/O/W MICROEMULSIONS FOR OCULAR ADMINISTRATION | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2025-02-06 | — | — | US | disclosed |
| US-20240423937-A1 | METHODS OF TREATING PAIN AND USES THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2024-12-26 | — | — | US | disclosed |
| US-20240156765-A1 | METHODS OF NEUROPROTECTION AND USES THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2024-05-16 | — | — | US | disclosed |
| US-20240050371-A1 | W/O/W MICROEMULSIONS FOR OCULAR ADMINISTRATION | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2024-02-15 | — | — | US | disclosed |
| US-20240041808-A1 | METHODS OF NEUROPROTECTION AND USES THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2024-02-08 | — | — | US | disclosed |
| US-11826467-B2 | W/O/W microemulsions for ocular administration | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2023-11-28 | — | — | US | disclosed |
| WO-2006127592-A2 | USE OF HYDROXYLAMINE DERIVATES FOR INHIBITING VITRECTOMY-INDUCED CATARACTS | OTHERA PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| EP-1689354-A2 | AMELIORATION OF CATARACTS, MACULAR DEGENERATION AND OTHER OPHTHALMIC DISEASES | Othera Pharmaceuticals, Inc. (US) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005055926-A2 | AMELIORATION OF CATARACTS, MACULAR DEGENERATION AND OTHER OPHTHALMIC DISEASES | OTHERA PHARMACEUTICALS, INC. (US) | 2005-06-23 | — | — | WO | disclosed |
| US-20050131025-A1 | Amelioration of cataracts, macular degeneration and other ophthalmic diseases | COLBY PHARMACEUTICAL COMPANY | 2005-06-16 | — | — | US | disclosed |
| EP-1507826-A2 | AMELIORATION OF THE DEVELOPMENT OF CATARACTS AND OTHER OPTHALMIC DISEASES | Othera Pharmaceuticals, Inc. (US) | 2005-02-23 | — | — | EP | disclosed |
| US-20040002461-A1 | Amelioration of the development of cataracts and other ophthalmic diseases | COLBY PHARMACEUTICAL COMPANY | 2004-01-01 | — | — | US | disclosed |
| WO-2003096991-A2 | AMELIORATION OF THE DEVELOPMENT OF CATARACTS AND OTHER OPTHALMIC DISEASES | OTHERA PHARMACEUTICALS, INC. (US) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240041808-A1 | METHODS OF NEUROPROTECTION AND USES THEREOF | NLN, BDNF, GAP43 | GAA 1315/4885ESR1 4854/4885HTT 40/4885 |
| US-20060292190-A1 | Amelioration of vitrectomy-induced cataracts | CRYAB, CRYAA, VIM | GAA 1847/4885ESR1 4731/4885HTT 15/4885 |
| US-20240423937-A1 | METHODS OF TREATING PAIN AND USES THEREOF | ACHE, PDE6G, PTGES3 | GAA 1080/4885ESR1 4826/4885HTT 1470/4885 |
| US-20240156765-A1 | METHODS OF NEUROPROTECTION AND USES THEREOF | NLN, BDNF, GAP43 | GAA 1315/4885ESR1 4854/4885HTT 40/4885 |
| US-20050131025-A1 | Amelioration of cataracts, macular degeneration and other ophthalmic diseases | C1R, CRYAB, C9 | GAA 4234/4885ESR1 3747/4885HTT 331/4885 |
| US-20080312283-A1 | Use of Hydroxylamine Derivates for Inhibiting Vitrectomy-Induced Cataracts | CRYAB, CRYAA, HAAO | GAA 2623/4885ESR1 4617/4885HTT 6/4885 |
| US-20040002461-A1 | Amelioration of the development of cataracts and other ophthalmic diseases | PDE6D, PDE6H, CCR1 | GAA 3517/4885ESR1 4785/4885HTT 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.